Tamoxifen-related porphyria cutanea tarda

Author： Agarwal R.   Peters T.   Coombes R.   Vigushin D.  

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.19, Iss.2, 2002-06, pp. : 121-123

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.

Related content

Effects of Switching from Tamoxifen to Anastrozole on Tamoxifen-Related Endocrine Symptoms and Quality of Life: In Early Breast Cancer Patients

By Massacesi Cristian  

American Journal of Cancer, Vol. 5, Iss. 6, 2006-01 ,pp. : 433-440 (8)

Adis International

Access to resources Recommend Favorite

Tamoxifen and arrhythmia

By Slovacek Ladislav  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1431-1432 (2)

Humana Press, Inc

Access to resources Recommend Favorite

Whither Tamoxifen

By Edmonson J.H.  

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 1-3 (3)

Academic Press

Access to resources Recommend Favorite

Tamoxifen and Cataracts: A Null Association

By Bradbury Brian D.   Lash Timothy L.  

Breast Cancer Research and Treatment, Vol. 87, Iss. 2, 2004-09 ,pp. : 189-196 (8)

Springer Publishing Company

Access to resources Recommend Favorite

The rise of tamoxifen: Temporal and geographical trends of tamoxifen use in Ontario

By Palda V.A.   Goel V.   Sawka C.A.  

Breast Cancer Research and Treatment, Vol. 43, Iss. 1, 1997-03 ,pp. : 33-41 (9)

Springer Publishing Company

Access to resources Recommend Favorite